27 May 2026VideosRegulation & IndustryJohn Rearick, Cooley | Sarah Hogan, Cooley | Mark Shtilerman, Deerfield Management | Jennifer Burdman, Sauvegarder Investment Management | Kumar Govindaswamy, Kymera Therapeutics

WATCH: IP deal-making in life sciences—valuation, due diligence, and transaction strategies

Structuring successful IP transactions in the life sciences sector requires rigorous due diligence and sophisticated valuation models. This panel brings together deal-makers and valuation experts to share strategies for protecting value and enabling innovation in complex M&A and licensing deals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Regulation & Industry

G 1/25: EPO settles controversial patent description question

4 September 2026 Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.

Regulation & Industry

California votes for law to restrict use of genAI by lawyers

4 September 2026 Lawmakers support a bill that would place guardrails on lawyers’ use of generative AI for court filings, in a bid to clamp down on AI ‘hallucinations’ and inaccuracies.

Regulation & Industry

FDA targets faster generic approvals in drive to slash drug prices

27 August 2026 Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices.

More features

G 1/25: EPO settles controversial patent description question

California votes for law to restrict use of genAI by lawyers

10x Genomics wins latest round in Parse patent dispute

Sun Pharma import ban back in force after Squires intervention

White & Case life sciences co-leader moves firms

‘Busiest’ US district patent judge swaps bench for private practice

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

Tempus AI bid to derail DNA patent case hits snag

WATCH: IP deal-making in life sciences—valuation, due diligence, and transaction strategies

More on this story

Editor's picks

Editor's picks

More features